Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Nichi-Iko

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nichi-Iko's Japan sales performance.

AZ, Daiichi Sankyo’s Enhertu set fair for filing in gastric cancer

AZ, Daiichi Sankyo’s Enhertu set fair for filing in gastric cancer The two companies are splitting development and marketing costs for Enhertu as well as global profits, except in Japan where Daiichi Sankyo is keeping exclusive rights.

The changing nature of approvals – what does the future hold?

The changing nature of approvals – what does the future hold? In contrast, less than 20% of new drugs were filed first in each of the other regions (Europe, Japan, RoW).

BMS expands collaboration with Nektar, sending shares soaring

BMS expands collaboration with Nektar, sending shares soaring While Opdivo was the first PD-1 inhibitor to reach the market in Europe and Japan, Merck &Co’s Keytruda’s earlier entry in the US allowed it to top Opdivo

Merck strengthens KRAS stake with Taiho and Astex partnership

Merck strengthens KRAS stake with Taiho and Astex partnership Otsuka’s Taiho has retained co-commercialisation rights in Japan, with the option to promote in certain areas of South East Asia.

Wave’s challenge to Sarepta in Duchenne falls flat

Wave’s challenge to Sarepta in Duchenne falls flat The demise of Wave’s programmes leaves Japan’s Nippon Shinyaku Pharma as the main rival to Sarepta in DMD.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics